|
|
|
Malaria vaccine for children
Experiments with a new malaria vaccine from GlaxoSmithKline have shown effective protection for children for a period of at least 18 months. Though still several years from reaching the market, the promising new vaccine, Mosquirix, is the most advanced of a number of vaccine candidates in development.
Malaria kills one African child every 30 seconds, and doctors consider a vaccine as the best hope against the mosquito-borne disease.
According to researchers in Cameroon, the Mosquirix vaccine reduced cases of life-threatening malaria by 49%. In a group of Mozambique children treated in 2003, all clinical cases were reduced by 35%. During the 18 month result period the effectiveness of the vaccine did not wane.
(Source: Wall Street Journal, November 16, 2005)
|
|
|